ZIM Laboratories Limited announced the outcome of its board meeting held on August 6, 2026, approving the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. On a consolidated basis, the company reported revenue from operations of Rs. 94.18 Crores (Rs. 9,417.85 Lakhs) for the current quarter, registering a decrease of Rs. 11.09 Crores or 10.54% compared to the previous quarter (Q4 FY26) where revenue stood at Rs. 105.27 Crores (Rs. 10,527.34 Lakhs), but marking an increase of Rs. 22.42 Crores or 31.25% compared to the corresponding quarter of the previous year (Q1 FY26) which was Rs. 71.76 Crores (Rs. 7,175.61 Lakhs). The net profit/loss after tax for the current quarter stood at a net loss of Rs. 4.02 Crores (Rs. -401.70 Lakhs), representing a decline of Rs. 7.76 Crores or 207.41% sequentially compared to the net profit of Rs. 3.74 Crores (Rs. 373.99 Lakhs) reported in the previous quarter, and a decrease of Rs. 2.14 Crores or 114.25% compared to the net loss of Rs. 1.87 Crores (Rs. -187.49 Lakhs) recorded in the same quarter last year. Below is the summary of the financial result analysis:

ZIM Laboratories Limited is a research-oriented pharmaceutical company based in Nagpur, India, specializing in the manufacture and development of differentiated formulation products and drug delivery systems. The company operates state-of-the-art manufacturing facilities covering general finished formulations, cephalosporins, and specialized oral thin films (OTF), backed by a robust global presence through its subsidiaries and joint ventures across Europe, the Middle East, Australia, and other emerging markets.